Prestige Consumer Healthcare Inc.’s portfolio expansion, notably with the TheraTears OTC dry eye drop brand, is Akorn Inc.’s exit from consumer health, even though its lineup still includes an OTC drug and a dietary supplement.
Both US firms on 27 May announced an agreement for Prestige (PCH) to pay Akorn “a total enterprise value” of...







